Adam Logal

Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD.

Bio-Reference Laboratories, Inc. engages in the provision testing and related services to physicians, clinics, hospitals, long-term care facilities, employers, government units, and correctional institutions. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology, services, serology, radio-immuno analysis, toxicology, pap smears, tissue pathology and other tissue analysis. The firm focuses on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional health care. The company was founded by Marc D. Grodman in 1981 and is headquartered in Elmwood Park, NJ.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.